Fmr LLC Purchases 47,768 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

Fmr LLC grew its position in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 28.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 214,596 shares of the biopharmaceutical company’s stock after purchasing an additional 47,768 shares during the period. Fmr LLC’s holdings in Revance Therapeutics were worth $1,114,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in RVNC. Alpine Associates Management Inc. bought a new stake in Revance Therapeutics in the 3rd quarter worth about $21,605,000. LMR Partners LLP bought a new position in shares of Revance Therapeutics in the third quarter valued at approximately $11,648,000. Stonepine Capital Management LLC increased its position in shares of Revance Therapeutics by 41.7% during the second quarter. Stonepine Capital Management LLC now owns 2,800,000 shares of the biopharmaceutical company’s stock valued at $7,196,000 after acquiring an additional 823,658 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Revance Therapeutics by 43.0% during the second quarter. Federated Hermes Inc. now owns 2,237,505 shares of the biopharmaceutical company’s stock valued at $5,750,000 after acquiring an additional 672,803 shares during the last quarter. Finally, Integral Health Asset Management LLC bought a new stake in Revance Therapeutics during the second quarter worth $1,285,000. 97.70% of the stock is owned by institutional investors.

Revance Therapeutics Stock Up 0.3 %

Shares of NASDAQ:RVNC opened at $3.09 on Tuesday. The firm has a market capitalization of $324.15 million, a PE ratio of -1.60 and a beta of 0.81. The company has a 50-day moving average price of $4.56 and a two-hundred day moving average price of $4.49. Revance Therapeutics, Inc. has a twelve month low of $2.30 and a twelve month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $59.88 million for the quarter, compared to the consensus estimate of $67.73 million. Analysts anticipate that Revance Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Mizuho reduced their price objective on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday, December 10th. HC Wainwright restated a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a research report on Friday, November 8th. StockNews.com initiated coverage on shares of Revance Therapeutics in a research report on Thursday, December 12th. They issued a “hold” rating on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Finally, Barclays restated an “equal weight” rating and set a $7.00 price target (down previously from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Revance Therapeutics presently has an average rating of “Hold” and an average target price of $8.96.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.